Clinical research is the cornerstone for the development of drugs and medical treatments. However, the current practices of measuring a limited number of metabolites fail to consider potential interaction effects. Incorporation of metabolomics analysis in clinical trials has the potential to improve the outcome in several ways, e.g. better insights into the mechanisms of drug actions, explain why subjects react differently to the same treatment and hereby assist in the development of personalised medicine, or reveal important new biomarkers for use in diagnostics.
How we can help
MS-Omics has broad experience in the analysis of biological sample types such as saliva, faeces, caecum, urine, and blood (plasma or serum). Our techniques cover a wide range of cell metabolites as well as drugs and their related metabolites.
Currently MS-Omics participates in two EU projects within clinical metabolomics; “Long-term impact of gestational and early-life dietary habits on infant gut immunity and disease risk” (in short EarlyFood) and “Faecal Microbiome as determinant of the effect of diet on colorectal cancer risk: comparison of meat based versus pesco-vegetarian diets” (in short MeaTIc). You can read more about the projects here.